Table 3.
Viral (n = 409) (75%) |
Influenza virus (A or B) (n = 187) Rotavirus (n = 140) HHV6 (n = 16) Adenovirus (n = 10) COVID 19 (n = 10) Mumps (n = 8) Respiratory-syncytial virus (n = 6) Epstein-Barr virus (n = 4) Viral gastroenteritis unspecified (n = 4) Other (n = 24) |
Bacterial (n = 40) (7%) |
Mycoplasma pneumoniae (n = 15) Enterococcus faecalis (n = 5) Escheria coli (n = 4) Other (n = 16) |
Seizure or epilepsy (n = 19) (4%) |
Benign infantile epilepsy (n = 2) Other (n = 17) |
Electrolyte disbalance (n = 18) (3%) | Hyponatremia (n = 18) |
Vascular (n = 13) (2%) | Kawasaki disease (n = 13) |
Drugs, toxins, and vaccination (n = 12) (2%) |
Mumps vaccination (n = 6) other (n = 6) |
Traumatic (n = 10) (2%) |
Diffuse axonal injury (n = 9) Unspecified (n = 1) |
Autoimmune (n = 4) (1%) |
Anti-GFAP encephalitis (n = 2) Systematic lupus erythematosus (n = 2) |
Various causes (n = 17) (3%) |
Acute encelopathy in congenital adrenal hyperplasia (n = 3) Thyroid crisis (n = 2) other (n = 12) |
In 542 pediatric patients, an associated disease was identified; in 395 patients, no associated disease entity could be identified (number of subjects per associated disease is reported in brackets). Only diseases which occurred more than once or are of special interest are listed in this table; for a detailed list, see the supplementary data
GFAP antibodies glial fibrillary acidic protein antibodies, HHV6 human herpes virus 6, SLE systemic lupus erythematosus